Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Gilgen, N; Farah, A; Scheller, B; Ohlow, MA; Mangner, N; Weilenmann, D; Wöhrle, J; Jamshidi, P; Leibundgut, G; Möbius-Winkler, S; Zweiker, R; Krackhardt, F; Butter, C; Bruch, L; Kaiser, C; Hoffmann, A; Rickenbacher, P; Mueller, C; Stephan, FP; Coslovsky, M; Jeger, R; BASKET-SMALL 2 Investigators.
Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2.
Clin Cardiol. 2018; 41(5):569-575 Doi: 10.1002/clc.22942 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Zweiker Robert

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

The treatment of coronary small vessel disease (SVD) remains an unresolved issue. Drug-eluting stents (DES) have limited efficacy due to increased rates of instent-restenosis, mainly caused by late lumen loss. Drug-coated balloons (DCB) are a promising technique because native vessels remain structurally unchanged. Basel Stent Kosten-Effektivitäts Trial: Drug-Coated Balloons vs. Drug-Eluting Stents in Small Vessel Interventions (BASKET-SMALL 2) is a multicenter, randomized, controlled, noninferiority trial of DCB vs DES in native SVD for clinical endpoints. Seven hundred fifty-eight patients with de novo lesions in vessels <3 mm in diameter and an indication for percutaneous coronary intervention such as stable angina pectoris, silent ischemia, or acute coronary syndromes are randomized 1:1 to angioplasty with DCB vs implantation of a DES after successful initial balloon angioplasty. The primary endpoint is the combination of cardiac death, nonfatal myocardial infarction, and target-vessel revascularization up to 1 year. Secondary endpoints include stent thrombosis, Bleeding Academic Research Consortium (BARC) type 3 to 5 bleeding, and long-term outcome up to 3 years. Based on clinical endpoints after 1 year, we plan to assess the noninferiority of DCB compared to DES in patients undergoing primary percutaneous coronary intervention for SVD. Results will be available in the second half of 2018. This study will compare DCB and DES regarding long-term safety and efficacy for the treatment of SVD in a large all-comer population. © 2018 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Angioplasty, Balloon, Coronary - adverse effects
Angioplasty, Balloon, Coronary - instrumentation
Angioplasty, Balloon, Coronary - mortality
Cardiac Catheterization - adverse effects
Cardiac Catheterization - instrumentation
Cardiac Catheterization - mortality
Cardiac Catheters -
Cardiovascular Agents - administration & dosage
Cardiovascular Agents - adverse effects
Clinical Protocols -
Coated Materials, Biocompatible -
Coronary Restenosis - etiology
Coronary Stenosis - diagnostic imaging
Coronary Stenosis - mortality
Coronary Stenosis - therapy
Drug-Eluting Stents -
Equipment Design -
Europe -
Female -
Humans -
Male -
Middle Aged -
Prospective Studies -
Research Design -
Risk Factors -
Severity of Illness Index -
Time Factors -
Treatment Outcome -

Find related publications in this database (Keywords)
Coronary Artery Disease
Drug-Coated Balloon
Randomized Controlled Trial
Small Coronary Vessel
Trial Design
© Med Uni Graz Impressum